Skip to content
ppharmaranks
Menu

Best treatments for bacteroides infections

26 products may treat bacteroides infections, spanning FDA drug classes such as cephalosporin antibacterial, lincosamide antibacterial, fluoroquinolone antibacterial. The current highest-rated option is cefotan. Ranked below by our independent recall-safety rating (rated where FDA data exists) — not medical advice; always consult a professional.

Quick answer: Of the 26 drugs we list for bacteroides infections, 22 are available as lower-cost generics, spanning classes such as cephalosporin antibacterial, lincosamide antibacterial, fluoroquinolone antibacterial. They’re ranked by each drug’s FDA recall-safety record — not clinical effectiveness for bacteroides infections — so confirm the right choice with your prescriber.

Rated against independent regulatory sources·Last updated August 19, 2026·How we rate

Understanding bacteroides infections

"Bacteroides Infections" is a medical-index label, not a disease people are usually told they have. It covers illness caused by Bacteroides, anaerobic gut bacteria that live in almost everyone. According to StatPearls (NCBI Bookshelf), Bacteroides fragilis is an obligate anaerobic gram-negative bacillus and part of the normal microbiota of the human colon; of the anaerobes there, "approximately 25% are species of Bacteroides," and in one longitudinal analysis of stool from 15 healthy adults, B. fragilis "was cultured from 87% of the cohort." That is the point most people get wrong: finding Bacteroides in the gut is normal. It becomes an infection only when the mucosal barrier fails — StatPearls states that disruption "either by inflammation, trauma, or surgery" and spread of the organism "to the bloodstream or surrounding tissues results in clinically significant infection." The syndromes StatPearls lists include intra-abdominal infection and abscess formation, bacteremia, chronic pressure ulcers and diabetic foot ulcers, necrotizing fasciitis, pyogenic arthritis and endocarditis. It is not trivial: StatPearls reports that Bacteroides species are found in most anaerobic infections, "with an associated mortality of more than 19%," and puts the overall crude mortality of B. fragilis bacteremia at 30.7%. Two facts change what happens next. First, penicillin fails, because B. fragilis produces beta-lactamase; StatPearls adds that cefoxitin, moxifloxacin and clindamycin "have low levels of susceptibility for Bacteroides fragilis, whereas Piperacillin/tazobactam, meropenem, and metronidazole have high susceptibility rates." Second, diagnosis depends on the specimen: "Needle aspiration and tissue biopsy are the best materials for anaerobic cultures," StatPearls says — so a surface wound swab can mislead. The IDSA 2024 intra-abdominal infection guideline suggests obtaining an abdominal CT as the initial diagnostic imaging modality when an acute intra-abdominal abscess is suspected in adults, and an abdominal ultrasound first in children (both conditional recommendations). StatPearls sums up management as source control plus targeted antimicrobial therapy, "the two keys to control Bacteroides fragilis infection." This is general information, not medical advice.

First-line treatment

Antibiotics alone are not the plan. The Surgical Infection Society's 2024 guideline on intra-abdominal infection recommends "undertaking source control within 12 hours in lower risk patients" and "within six hours in higher risk patients with associated septic shock" — meaning drainage or surgery to remove the infected collection. For empiric drug therapy, the same SIS guideline recommends "metronidazole as the preferred anti-anaerobic agent in combination regimens," and names piperacillin-tazobactam, imipenem-cilastatin or meropenem, and ceftazidime-avibactam or ceftolozane-tazobactam combined with metronidazole. Treatment is shorter than many people expect: SIS recommends limiting therapy to four days once source control is achieved by percutaneous drainage, and suggests eight days in critically ill patients. Regimen choice belongs to the treating clinician.

Top-rated picks for bacteroides infections: 1. Cefotan · 2. Clindesse · 3. Vigamox

Top-rated treatments for bacteroides infections, ranked by pharmaranks score
#DrugRatingPharmacy pays
170/100View →
270/100$0View →
370/100$2View →
470/100$0View →
568/100$4View →
664/100$0View →
764/100$0View →
864/100$0View →
958/100$0View →
1056/100$0View →

Full ranking · 26 treatments

PAI HOLDINGS PHARM logo
#3 of 19 in Cephalosporin Antibacterial

cefotan

PrescriptionFDA-sourced

70/100

Cefotan (Cefotetan Disodium) is a cephalosporin antibacterial used to treat Abscess, Bacteroides Infections, Human Bites, Infectious Bone Diseases.

(2 data points)
cephalosporin antibacterialabscessbacteroides infections

Price varies

View details →
PADAGIS US logo
#1 of 7 in Lincosamide Antibacterial

clindesse

PrescriptionFDA-sourced

70/100

Clindesse (Clindamycin Phosphate) is a lincosamide antibacterial used to treat Acne Vulgaris, Actinomycetales Infections, Bacteroides Infections, Pneumocystis Pneumonia.

(3 data points)
lincosamide antibacterialacne vulgarisactinomycetales infections

Pharmacy pays

From ~$0.11· 6 forms
View details →
#1 of 3 in Fluoroquinolone Antibacterial

vigamox

PrescriptionFDA-sourced

70/100

Vigamox (Moxifloxacin Hydrochloride) is a fluoroquinolone antibacterial used to treat Bacteroides Infections, Bronchitis, Cystitis, Escherichia Coli Infections.

(1 data points)
fluoroquinolone antibacterialquinolone antimicrobialbacteroides infections

Pharmacy pays

From ~$1.64· 2 forms
View details →
ORGANON logo
#1 of 7 in Lincosamide Antibacterial

xaciato

PrescriptionFDA-sourced

70/100

Xaciato (Clindamycin Phosphate) is a lincosamide antibacterial used to treat Acne Vulgaris, Actinomycetales Infections, Bacteroides Infections, Pneumocystis Pneumonia.

(1 data points)
lincosamide antibacterialacne vulgarisactinomycetales infections

Pharmacy pays

From ~$0.11· 6 forms
View details →
SANDOZ logo
#2 of 3 in Fluoroquinolone Antibacterial

ciloxan

PrescriptionFDA-sourced

68/100

Ciloxan (Ciprofloxacin Hydrochloride) is a fluoroquinolone antibacterial used to treat Anthrax, Infectious Arthritis, Bacteroides Infections, Campylobacter Infections.

(23 data points)
fluoroquinolone antibacterialquinolone antimicrobialanthrax

Pharmacy pays

From ~$2.64/30· 5 forms
View details →
PFIZER logo
#3 of 7 in Lincosamide Antibacterial

cleocin

PrescriptionFDA-sourced

64/100

Cleocin (Clindamycin Phosphate) is a lincosamide antibacterial used to treat Acne Vulgaris, Actinomycetales Infections, Bacteroides Infections, Pneumocystis Pneumonia.

(61 data points)
lincosamide antibacterialacne vulgarisactinomycetales infections

Pharmacy pays

From ~$0.11· 6 forms
View details →

Frequently asked

What treats bacteroides infections?
Our catalog lists 26 products that may treat bacteroides infections, based on NIH RxClass (MED-RT “may treat”) drug-classification data — not the verbatim FDA label. They're rated where FDA recall-safety data exists; the current top-rated option is cefotan.
What is the best-rated treatment for bacteroides infections?
By our independent recall-safety rating — not an efficacy measure — cefotan ranks highest among the products we list for bacteroides infections. Always consult a professional.
How are these treatments ranked?
By our independent score, currently based on FDA regulatory recall-safety data (the methodology blends additional sources as they come online). See the How we rate page.
What types of drugs treat bacteroides infections?
Treatments for bacteroides infections span FDA drug classes including cephalosporin antibacterial, lincosamide antibacterial, fluoroquinolone antibacterial, quinolone antimicrobial, nitroimidazole antimicrobial. Compare every option side by side, ranked by independent rating, above.

Treatment associations are derived from NIH RxClass (MED-RT “may treat”) drug-classification data — not the verbatim FDA label. This is general reference, not medical advice — always consult a licensed professional.

Sources

The clinical overview above is written from these authoritative public-health and medical-society sources, independently reviewed against each.